Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference.
The presentation will take place as follows:
- Date & Time: Wednesday April 25th at 4:40 pm EST
- Title: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases”
- Venue: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S.
Pharnext’s team will also attend the 2018 American Academy of Neurology Annual Meeting as a first-time exhibitor (booth 908). The meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S.
If you are interested in meeting the Pharnext management team during these events, please send an email to contact@pharnext.com.
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company developing novel therapeutics for orphan and
common neurodegenerative diseases that currently lack curative and/or
disease-modifying treatments. Pharnext has two lead products in clinical
development. PXT3003 is currently in an international Phase 3 trial for
the treatment of Charcot-Marie-Tooth disease 1A type and benefits from
orphan drug status in Europe and the United States. The results of this
trial are expected in the second half of 2018. PXT864 has generated
positive Phase 2 results in Alzheimer’s disease. Pharnext has developed
a new drug discovery paradigm based on big data genomics and artificial
intelligence: PLEOTHERAPY™. The Company identifies and develops synergic
combinations of drugs called PLEODRUG™ offering several key advantages:
efficacy, safety and robust intellectual property. The Company was
founded by renowned scientists and entrepreneurs including Professor
Daniel Cohen, a pioneer in modern genomics, and is supported by a
world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
code: FR0011191287).
For more information, visit www.pharnext.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180419005935/en/
Contact information
Pharnext
Xavier Paoli
Chief Commercial Officer
+33
(0)1 41 09 22 3030
contact@pharnext.com
or
Investor
Relations (Europe)
MC Services AG
Anne Hennecke
+49
211 529252 22
anne.hennecke@mc-services.eu
or
Investor
Relations (U.S.)
Stern Investor Relations, Inc.
Matthew
Shinseki
+1 212 362 1200
matthew@sternir.com
or
Financial
Communication (France)
Actifin
Stéphane Ruiz
+33 (0)1
56 88 11 15
sruiz@actifin.fr
or
Media
Relations (Europe)
ALIZE RP
Aurore Gangloff
Caroline
Carmagnol
+33 (0)1 44 54 36 66
pharnext@alizerp.com
or
Media
Relations (U.S.)
RooneyPartners
Kate Barrette
+1 212
223 0561
kbarrette@rooneyco.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mandate of BaFin’s special commissioner at flatexDEGIRO terminated18.10.2024 18:25:00 EEST | Press release
Mandate of BaFin’s special commissioner at flatexDEGIRO terminated The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special commissioner. flatexDEGIRO AG made this announcement on October 18, 2024, following a corresponding decision by the German Federal Financial Supervisory Authority (BaFin). Oliver Behrens, CEO of flatexDEGIRO, said: “We have realigned and sustainably strengthened our organizational structures and processes in constructive cooperation with BaFin and the special commissioner. We are thereby closing a regulatory chapter and again increase our focus on our customers and important growth projects. My special thanks go to all employees who, under the leadership of Steffen Jentsch, member of the bank's management board, have made it possible to reach th
Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication18.10.2024 17:00:00 EEST | Press release
Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows. BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair. “
Gurobi Brings Decision Intelligence Summit to Amsterdam18.10.2024 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is set to host the first annual EMEAI Decision Intelligence Summit (“Gurobi Summit”) at Amsterdam’s Capital C on November 5-6, 2024. Following the success of last month’s inaugural summit for the Americas in Las Vegas, the EMEAI Summit will bring together operations researchers, data scientists, and business leaders from across the region to explore the latest advancements in mathematical optimization and decision intelligence. The Gurobi Summit will feature special presentations from companies such as Accenture and ICRON. Several of the company’s partners—including Decide4AI, Decision Labs, LTPLabs, and ORMAE—will also be present to showcase their solutions and insights. The two-day event will be packed with informative presentations, exciting customer case studies, and interactive learning opportunities. Day 1 will feature keynotes, technical presentations, and panel discussions. Day 2 will be dedicated to hand
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting18.10.2024 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation on Sunday, October 20, during the “Best Abstract” session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET. Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be present
SLB Announces Third-Quarter 2024 Results18.10.2024 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016795721/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2024Jun. 30, 2024Sept. 30, 2023SequentialYear-on-yearRevenue $9,159 $9,139 $8,310 - 10% Income before taxes - GAAP basis $1,507 $1,421 $1,395 6% 8% Income before taxes margin - GAAP basis 16.5% 15.5% 16.8% 91 bps -33 bps Net income attributable to SLB - GAAP basis $1,186 $1,112 $1,123 7% 6% Diluted EPS - GAAP basis $0.83 $0.77 $0.78 8% 6% Adjusted EBITDA* $2,343 $2,288 $2,081 2% 13% Adjusted EBITDA margin* 25.6% 25.0% 25.0% 55 bps 54 bps Pretax segment operating income* $1,902 $1,854 $1,683 3% 13% Pretax segment operating margin* 20.8% 20.3% 20.3% 48 bps 51 bps Net income attributable to SLB, excluding charges & cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom